Iovance Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock Public Offering Read more about Iovance Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock Public Offering
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock Read more about Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock Read more about Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock
Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers Read more about Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers
Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results Read more about Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results
Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017 Read more about Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017
Iovance Biotherapeutics Expands Pipeline of TIL Therapies into Lung Cancer Read more about Iovance Biotherapeutics Expands Pipeline of TIL Therapies into Lung Cancer
Iovance Biotherapeutics Announces Six Abstracts to be Presented at the Upcoming 2017 SITC Annual Meeting Read more about Iovance Biotherapeutics Announces Six Abstracts to be Presented at the Upcoming 2017 SITC Annual Meeting
Iovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management Read more about Iovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management
Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results Read more about Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results